The sudden resolution of a well-known conjecture highlights the growing adoption of AI as an assistant in high-level ...

In a Massachusetts school district, by 2021, after years of decline on the state test, only 12 percent of middle schoolers ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

👉Learn how to factor quadratics using the difference of two squares method. When a quadratic contains two terms where each of the terms can be expressed as the square of a number and the sign between ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada ‌ ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...

Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...

Axiom Math is giving away a powerful new AI tool. But it remains to be seen if it speeds up research as much as the company hopes. Axiom Math, a startup based in Palo Alto, California, has released a ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide. The FDA has authorized the first generic version of fluticasone ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. ProPublica on Friday published never-before-released data ...

Affordable, regulated versions of Ozempic, the well-known diabetes and weight-loss shot from Novo Nordisk, are about to hit markets around the world, which could shake up the obesity drug scene. The ...